Takeshi Enomoto Selected Research

Cognitive Dysfunction

1/2018	Discovery and Development of Muscarinic Acetylcholine M4 Activators as Promising Therapeutic Agents for CNS Diseases.
5/2016	The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets.
1/2008	Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats.
7/2007	Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment.
12/2005	Long-lasting impairment of associative learning is correlated with a dysfunction of N-methyl-D-aspartate-extracellular signaling-regulated kinase signaling in mice after withdrawal from repeated administration of phencyclidine.
7/2005	Pre-Injury magnesium treatment prevents traumatic brain injury-induced hippocampal ERK activation, neuronal loss, and cognitive dysfunction in the radial-arm maze test.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takeshi Enomoto Research Topics

Disease

10	Schizophrenia (Dementia Praecox) 12/2019 - 12/2005
6	Cognitive Dysfunction 01/2018 - 07/2005
3	Psychotic Disorders (Schizoaffective Disorder) 08/2013 - 07/2007
2	Neurobehavioral Manifestations 12/2019 - 06/2009
1	Dyskinesias (Dyskinesia) 01/2021
1	Parkinson Disease (Parkinson's Disease) 01/2021
1	Central Nervous System Diseases (CNS Diseases) 01/2018
1	Brain Injuries (Brain Injury) 07/2005
1	Traumatic Brain Injuries (Traumatic Brain Injury) 07/2005
1	Brain Ischemia (Cerebral Ischemia) 08/2004
1	Brain Contusion 08/2004

Drug/Important Bio-Agent (IBA)

3	Antipsychotic Agents (Antipsychotics)IBA 01/2018 - 12/2005
3	N-Methylaspartate (NMDA)IBA 05/2016 - 07/2007
3	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 05/2016 - 12/2005
3	Phencyclidine (Angel Dust)IBA 06/2009 - 12/2005
2	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2021 - 12/2019
2	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2018 - 02/2013
2	Ketamine FDA LinkGeneric 05/2016 - 06/2009
2	blonanserinIBA 05/2016 - 01/2015
2	Dopamine D3 ReceptorsIBA 05/2016 - 03/2015
2	MagnesiumIBA 07/2005 - 08/2004
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 01/2021
1	Levodopa (L Dopa)FDA LinkGeneric 01/2021
1	Cholinergic Agents (Cholinergics)IBA 01/2018
1	LigandsIBA 01/2018
1	Pharmaceutical PreparationsIBA 01/2018
1	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2018
1	Haloperidol (Haldol)FDA LinkGeneric 01/2015
1	tandospironeIBA 01/2015
1	Risperidone (Risperdal Consta)FDA LinkGeneric 01/2015
1	5-HT1A Serotonin ReceptorIBA 01/2015
1	Methamphetamine (Desoxyn)FDA LinkGeneric 02/2013
1	Apomorphine FDA Link 02/2013
1	GABA-A Receptors (GABA(A) Receptor)IBA 03/2011
1	BicucullineIBA 03/2011
1	gamma-Aminobutyric Acid (GABA)IBA 03/2011
1	Dopamine (Intropin)FDA LinkGeneric 03/2011
1	Lurasidone Hydrochloride FDA Link 01/2008
1	SolutionsIBA 07/2005
1	salicylhydroxamic acid (SHAM)IBA 07/2005
1	Dihydrotachysterol (AT 10)IBA 07/2005
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 07/2005
1	Neuroprotective AgentsIBA 08/2004

Therapy/Procedure

1	Therapeutics 01/2015
1	Oral Administration 08/2013